流感疫苗和鸡蛋过敏更新

根据澳大利亚临床免疫学和过敏症学会的最新指南,可以在社区疫苗接种诊所(可能有也可能没有直接的医生监督)安全地为有和没有鸡蛋过敏(包括鸡蛋过敏反应)的人接种流感疫苗。这是单剂量,然后是推荐的 15 分钟观察期。请参考我们的 MVEC:过敏和免疫 页面了解更多详情。


New Zoster vaccine (Zostavax®) FAQs reference page

SAEFVIC has updated its Zoster resources and developed a new frequently asked questions (FAQ) page for use by providers. The Zoster vaccine FAQs page provides answers to questions on the use of Zostavax® and can be used in conjunction with existing resources in the Zoster MVEC page.

 


Updated Meningococcal page

MVEC's Meningococcal disease and vaccines page has been updated. Please note, we have now combined the pages for all Meningococcal vaccines under the one Immunisation reference page.

http://www.mvec.vic.edu.au/immunisation-references/meningococcal-disease-and-vaccines/


Zostavax - GP decision aid

Zostavax® contains a live attenuated varicella-zoster virus, containing 14 times more virus than childhood varicella vaccines. Administration to people who are immunocompromised is associated with risk of disseminated disease from the vaccine virus. Our new GP decision aid be used to assist in the identification of patients who may be contraindicated for the shingles vaccine.

For further info including new resources, please refer to our MVEC:带状疱疹 页。


Influenza vaccine recommendations for 2017

Flu season is now upon us! Please follow the link for the current influenza vaccine recommendations.

Influenza 2017 recommendations


Meningococcal disease

Meningococcal disease is caused by the bacteria 脑膜炎奈瑟菌。 There are 13 known sub-types (A, B, C, W and Y). In 2016, the main serotypes causing disease in Australia are B and W with variations noted by state. Importantly, they are both potentially vaccine preventable.

We have recently added a resource page for Meningococcal disease and vaccines to provide further information.


MTHFR gene explained

A number of families, consumers and healthcare professionals have been asking MVEC staff about the MTHFR gene (methylenetetrahydrofolate reductase) and possible adverse events following immunisation [AEFI]. Please refer to our MVEC page 了解更多信息。


New Zoster (Shingles) Immunisation Program

From November 2016, Zostavax will be funded under the National Immunisation Program for persons aged 70 years, with catch-up for those aged 71–79 years also funded until October 2021.

For further information, including our new resources please refer to our MVEC page


Victorian immunisation schedule app

Vicvax is our new Victorian immunisation schedule app for smart phones. Please refer to the MVEC homepage for details


Allergy and immunisation reference page

For further information about allergies and the immunisation process please refer to our new reference page 过敏和免疫